BURNABY, BRITISH COLUMBIA--(Business Wire / Korea Newswire)--ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed. This acquisition further enhances the vertical integration of Telix’s supply chain and manufacturing by providing a greater level of supply chain and regulatory control over the production of key isotopes.

ARTMS will support the high efficiency, large-scale and cost-effective production of commercially important medical isotopes for Telix’s portfolio of products, such as zirconium-89 (89Zr), gallium-68 (68Ga), technetium‐99m (99mTc) and copper-64 (64Cu), and will continue to partner with additional radiopharmaceutical companies to ensure that these critical isotopes are available on demand for patients. In addition, ARTMS’ portfolio of advanced cyclotron technologies has immediate application and differentiation for Telix in the production of future commercially important alpha-emitting, therapeutic isotopes, including actinium-225 (225Ac) and astatine-211 (211At).

The history of ARTMS is rooted in a Canadian government funded project focused on solid target production of 99mTc. After that project was successfully completed, the innovation continued and resulted in a full suite of PET products. In 2017, ARTMS Inc. was formed with support and seed funding from Quark Venture, through their Global Health Sciences Fund (GHS) and founding institutions TRIUMF, BC Cancer, Lawson Health Research Institute and the Center for Probe Development. In May of 2020, ARTMS completed a $20M USD Series A fundraising that included GHS and welcomed Deerfield Management to the ARTMS family. In the subsequent years ARTMS has played a critical role in alternative production of medical isotopes with a focus on accelerating the production capabilities of the world’s most commonly installed cyclotrons. The collaboration between ARTMS’ unparalleled team, its investors and founding members has resulted in a truly differentiated organization.

Solomon Partners Securities LLC acted as financial advisor and Norton Rose Fulbright Canada LLP acted as legal advisor to ARTMS during the negotiations and due diligence process related to the acquisition by Telix.

About ARTMS,

Based in Burnaby, British Columbia, Canada, ARTMS Inc. is the global leader in the development of novel technologies and products which enable the high-quality and high-yield production of the world’s most-used diagnostic imaging isotopes. ARTMS’ flagship product, the QUANTM Irradiation System (QISTM), enables decentralized, cost-effective, large-scale production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium‐99m (99mTc) and copper-64 (64Cu) using pharmaceutical distributor and hospital-based medical cyclotrons, empowering users to control their supply chain. ARTMS commercializes these award-winning and proprietary Canadian inventions on a global basis and has the prospect of revolutionizing the nuclear medicine industry.

For more information on the QUANTM Irradiation System™ and ARTMS, please follow us on Twitter/X @ARTMS_Inc/X and LinkedIn and visit http://www.artms.ca/

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411054954/en/

Website: https://www.artms.ca/ View Korean version of this release Contact ARTMS Corporate Contact
ARTMS, Inc.
Douglas Gentilcore
Chief Executive Officer
gentilcore@artms.ca

ARTMS Commercial Contact
Kevin Reimer
VP Global Sales and Marketing
reimer@artms.ca

Telix Investor Relations
Telix Pharmaceuticals Limited
Ms. Kyahn Williamson
SVP Investor Relations and Corporate Communications
kyahn.williamson@telixpharma.com
This news is a press release provided by ARTMS Inc.. Korea Newswire follows these editorial guidelines. ARTMS Inc. News ReleasesSubscribeRSS 텔릭스 파마슈티컬스, ARTMS 인수 완료 ARTMS(ARTMS Inc.)(이하 ARTMS)가 텔릭스 파마슈티컬스(Telix Pharmaceuticals Limited)(이하 텔릭스)에 의한 인수가 완료되었음을 발표했다. 이번 인수는 주요 동위원소 생산에 대한 더 높은 수준의 공급망 및 규제 통제를 제공함으로써 텔릭스의 공급망 및 제조의 수직적 통합을 더욱 강화한다. ARTMS는 지... 4월 12일 15:00 More News Health Medical Appliances Mergers & Acquisitions Overseas ARTMS Inc. All News Releases 